Sharemaestro Newsreel

Kestra Medical Technologies (NASDAQ: KMTS) CFO trades 26,287 shares in 10b5-1 sales

Kestra Medical Technologies CFO Vaseem Mahboob sold 26,287 common shares of KMTS in two open-market transactions on August 7, 2026. These sales were conducted under a Rule 10b5-1 trading plan established on November 6, 2025. The shares were sold at weighted average prices of …

Sanara Medtech earnings missed by $0.02, revenue fell short of estimates

Deadline Alert: Embecta Corp. (EMBC) Shareholders Who Lost

Glancy Prongay Wolke & Rotter LLP has issued a deadline alert for investors of Embecta Corp. (EMBC) who suffered losses. Shareholders who purchased securities between November 25, 2025, and May 4, 2026, are urged to contact the firm regarding a securities fraud lawsuit, with …

Solventum Corp. stock falls Tuesday, underperforms market

Solventum Corp. (SOLV) shares dropped 1.30% to $84.10 on Tuesday, underperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average also saw declines. This fall ended a two-day winning streak for the stock.

Sanara MedTech (SMTI) grows H1 2026 revenue to $55.9M and trims loss

Sanara MedTech Inc. (SMTI) reported significant revenue growth for the first half of 2026, reaching $55.9 million, primarily driven by strong sales of its soft tissue repair products. The company also substantially reduced its net loss attributable to shareholders, nearly breaking even with a …

Sanara MedTech Inc. Q2 2026: Revenue $28.14M, EPS $(0.05) — 10-Q Summary

Sanara MedTech Inc. reported its Q2 2026 financial results, with revenue reaching $28.14M, a 9.1% increase year-over-year. The company posted a diluted loss per share of $(0.05), an improvement from $(0.23) in Q2 2025. This growth was primarily driven by surgical soft tissue repair …

Alcon Inc (ALC) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Strategic Pivots ...

This article first appeared on GuruFocus. Release Date: August 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Alcon Inc (NYSE:ALC) delivered 7% sales growth in Q2 2026, driven by broad-based strength across …

AngioDynamics at Canaccord Genuity conference: growth pivot deepens

AngioDynamics discussed its strategic pivot from a legacy catheter business to a high-growth MedTech portfolio at the Canaccord Genuity conference. The company highlighted 18% MedTech revenue growth in fiscal 2026, now comprising 47% of total revenue, and projected 12-15% MedTech growth for fiscal 2027. …

Teleflex Inc. stock underperforms Monday when compared to competitors

Teleflex Inc. (TFX) stock declined by 1.47% on Monday, closing at $133.00, despite a generally poor trading session for the broader market. This marks the second consecutive day of losses for the company. The S&P 500 Index (SPX) fell 0.06% and the Dow Jones …

Align Names Noel Kilcooley CTO to Lead AI and Technology Strategy

Align has appointed Noel Kilcooley as Chief Technology Officer, entrusting him with the company's technology strategy, AI initiatives, cybersecurity, and compliance. This move positions Align to support clients navigating complex infrastructure demands driven by AI adoption. Kilcooley, a 25-year veteran of the company, will …

Sanara MedTech Inc. (SMTI) Releases Q2 2026 Earnings: Revenue Rises 8.9%

Sanara MedTech Inc. (SMTI) reported an 8.9% increase in revenue for Q2 2026, reaching $28.1 million, with gross profit rising to $26.2 million. Despite strong top-line growth, the company posted a net loss of $(0.05) per diluted share. The article also details hedge fund …

INTUITIVE SURGICAL INC SEC Filing (Aug 11, 2026)

This article reports on an SEC Form 144 filing by INTUITIVE SURGICAL INC (ISRG) dated August 11, 2026. The filing indicates a proposed sale of 20,095 shares of common stock with an aggregate market value of $7,904,971.10. These securities were acquired on February 10, …

AtriCure (NASDAQ:ATRC) Sets New 12-Month High - Here's Why

AtriCure (NASDAQ:ATRC) reached a new 52-week high of $43.18, trading above its 50-day and 200-day moving averages. The company reported strong quarterly earnings, exceeding revenue estimates with $153.6 million and $0.18 EPS. Despite significant institutional ownership, insiders have sold shares totaling $1.78 million in …

ATRC: Strong growth, innovation, and clinical trial catalysts drive robust financial and market expansion

AtriCure, Inc. (ATRC) is experiencing strong growth and profitability, maintaining leadership in AFib and pain management. The company's financial performance is bolstered by innovation and operational leverage, with significant clinical trials expected to expand market opportunities. Free cash flow will be directed towards organic …

Anteris Technologies Global (NASDAQ:AVR) Releases Earnings Results, Misses Estimates By $0.09 EPS

Anteris Technologies Global (NASDAQ:AVR) reported its quarterly earnings, missing analyst estimates with an EPS loss of $0.30, which was $0.09 worse than expected, and revenue of $1.01 million, below the $1.50 million estimate. Despite the missed earnings, analysts maintain a "Moderate Buy" rating with …

Anteris Technologies (AVR) boosts cash to $260.9M while losses mount in DurAVR valve push

Anteris Technologies reported a Q2 2026 operating loss of $55.0 million and a net loss of $51.7 million, with increased R&D and SG&A expenses driven by the DurAVR® transcatheter heart valve system development and global pivotal trial. Despite these losses, the company significantly boosted …

Femasys (FEMY) secures $30M private placement with extensive warrant package and board rights

Femasys Inc. has secured a $30 million private placement through the sale of common stock and a significant package of pre-funded and accompanying warrants to accredited investors. The deal includes board designation rights for lead investor Nantahala Capital Management and involves participation from five …

Harvard Bioscience (NASDAQ: HBIO) grows Q2 sales but faces higher debt costs

Harvard Bioscience (NASDAQ: HBIO) reported an 11.1% increase in Q2 2026 revenue, reaching $22.7 million, primarily driven by strong sales to CROs in the Americas and distributors in Asia-Pacific. Despite revenue growth and ongoing cost-saving initiatives like "Project Viking," the company posted a net …

HARVARD BIOSCIENCE INC 2026: Revenue $22.73M, EPS ($0.64) — 10-Q Summary

HARVARD BIOSCIENCE INC (HBIO) reported its second-quarter 2026 results, showing an 11.1% year-over-year revenue increase to $22.73M. Despite this growth, the company recorded a net loss of ($2.91M) and a diluted loss per share of ($0.64). The revenue growth was primarily driven by increased …

Sanara MedTech (SMTI) grows revenue, posts Q2 loss amid pending MIMEDX deal

Form 8K Sanara Medtech Inc For: 11 August By Investing.com

This article reports on the filing of a Form 8K by Sanara Medtech Inc. on August 11, 2026. The brief announcement from Investing.com indicates this as a significant event for shareholders and market watchers of SMTI.

MIMEDX Expected to Acquire Sanara MedTech, Pending Closing Conditions

Sanara MedTech reported a 9% increase in Q2 2026 net revenue to $28.1 million and a 14% rise for the first six months to $55.9 million, maintaining a 93% gross margin. The company also announced a signed agreement for its acquisition by MIMEDX, pending …

ICU Medical (ICUI) insider plans resale of 378 vested shares

An insider at ICU Medical Inc. (ICUI) plans to sell 378 shares of common stock, valued at $68,978.08, through Morgan Stanley Smith Barney LLC. These shares were acquired on May 13, 2020, as restricted stock vesting for services rendered. The filing indicates 25,007,000 shares …

ICU Medical (ICUI) files Form 144 for planned sale of 8,929 shares

ICU Medical, Inc. (ICUI) has filed a Form 144 indicating a planned resale of 8,929 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares, valued at approximately $1,633,403.62, are related to previously exercised options and vesting equity awards, …

DENTSPLY SIRONA (XRAY) SVP Frohning reports 802 tax-withheld shares

Andrea L. Frohning, SVP and CHRO of DENTSPLY SIRONA Inc. (XRAY), reported the disposition of 802 shares of common stock on August 7, 2026. These shares were withheld to cover taxes related to the vesting of her Restricted Stock Units and dividend equivalent units. …

PLSE: nsPFA technology delivers breakthrough efficacy in AFib and is poised for broad clinical adoption

Pulse Biosciences, Inc. (PLSE) is developing next-generation nsPFA technology for AFib treatment, demonstrating high efficacy and efficiency. The company's leadership, strong clinical data, competitive position, and partnership strategy are expected to drive broad clinical adoption. This information is based on an audio transcript from …

Margin Squeeze And Buybacks Might Change The Case For Investing In Avantor (AVTR)

Avantor, Inc. (AVTR) reported Q2 and first-half 2026 results showing increased sales but decreased net income, indicating margin compression. Despite the earnings squeeze, the company completed a significant share repurchase program, buying back 6,629,063 shares for US$74.97 million. This capital allocation decision raises questions …

AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

AngioDynamics, Inc. (ANGO) presented a slideshow at Canaccord Genuity's 46th Annual Growth Conference. The article, authored by SA Transcripts, highlights the company's participation in this event. SA Transcripts is responsible for publishing thousands of quarterly earnings call transcripts and other transcript-related projects on Seeking …

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

Rocket Pharmaceuticals RCKT reported earnings of $1.08 per share (including certain one-time items) in the second quarter of 2026 in contrast to a loss of 62 cents per share incurred in the year-ago quarter. The Zacks Consensus Estimate for the company's bottom line was …

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

Axsome Therapeutics AXSM incurred a loss of 99 cents per share in the second quarter of 2026, which was in line with the Zacks Consensus Estimate. The company had reported a loss of 97 cents per share in the year-ago quarter. Axsome's total revenues …

Microbot Medical Inc. Q2 2026: Revenue $241K, Net loss $5.63M — 10-Q Summary

Microbot Medical Inc. reported its Q2 2026 results, announcing its first commercial revenue of $241,000, a significant increase from zero in the previous year. Despite this, the company posted a net loss of $5.63 million, worsening from a $3.5 million loss in the prior-year …

Microbot Medical Q2 Results: Sales miss by 29%, EPS in line

Microbot Medical (NASDAQ: MBOT) reported Q2 EPS of $(0.08), meeting analyst estimates and showing a 20% improvement year-over-year. However, the company's sales of $241,000 significantly missed the estimated $340,000 by 29.12%, raising concerns about its top-line growth despite improved per-share losses. This discrepancy suggests …

Harvard Bioscience targets 3% to 5% full-year 2026 revenue growth as CMT and China mix shifts gross margin to 57% to 59%

Earnings Call Insights: Harvard Bioscience (HBIO) Q2 2026 MANAGEMENT VIEW * "That disciplined focus and execution helped us deliver strong second quarter performance, highlighted by double-digit revenue growth across our CMT and preclinical portfolios and solid operational execution that reinforced our confidence in raising …

AngioDynamics Port Catheter Lawsuit

Wisner Baum is actively investigating claims against AngioDynamics and Navilyst Medical concerning implantable port catheters due to reported complications like infection, thrombosis, device fracture, and migration. The AngioDynamics Port Catheter MDL, centralized in California, has grown to over 400 pending actions as of July …

New Launches and Pipeline Investments Support Alcon's Market Leadership and Strong Fundamentals

Alcon, a leading vision care company, is strengthening its market position through new product launches and strategic pipeline investments. The company operates in two key segments: vision care and surgical. Recent performance indicates that innovations, particularly in its Unity products, are driving growth despite …

Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down

Hims & Hers Health, Inc. HIMS reported quarterly adjusted loss per share of 10 cents in second-quarter 2026, against the year-ago period's adjusted earnings per share (EPS) of 17 cents. The metric was wider than the Zacks Consensus Estimate of loss per share of …